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I NFECTION with the herpes group of viruses. in particular, cytomegalovirus 
(CMV), is a significant cause of morbidity 
and mortality in organ transplant recipients. 
Immunosuppressive regimens containing anti-
thymocyte globulin (ATG) have been shown 
to be associated with a higher frequency of 
symptomatic CMV disease.' Another anti-
lymphocyte preparation, OKT3, is a murine 
monoclonal antibody that has proved effica-
cious in treating allograft rejection. The pur-
pose of this study was to analyze the impact of 
OKT3 on the frequency and severity of CMV 
and herpes simplex virus (HSV) infections in 
adult liver transplant recipients. 
METHODS 
The study population consisted of 121 consecutive 
adult patients who underwent orthotopic liver transplan-
tation at our institution between January 1984 and Sep-
tember 1985, who survived for at least 72 hours postoper-
alively, and for whom preoperative serum samples were 
available. Standard immunosuppression consisted of 
cyclosporine (CsA) and corticosteroids (20 mg/d ofpred-
nisone). Rejection episodes were treated with additional 
steroids. Azathioprine (AzA) was usually administered to 
reduce the CsA dosage in patients experiencing nephro-
toxicity. For more severe degrees of rejection OKT3 was 
administered. 
CMV infection was diagnosed by virus isolation or by 
changes in serological ti ter (seroconversion or a fourfold 
or greater rise CMV antibody titer). Ninety-three 
patients were evaluable for CMV infection. Clinical 
diseases caused by CMV were of the following types: 
febrile viral syndrome, localized CMV disease, and dis-
seminated CMV disease. HSV infection was defined as 
the presence of typical symptomatic oral/ genital ulcers or 
histological evidence of tissue invasion. Ninety-five of 121 
patients were seropositive for HSV antibodies pretrans-
plant. 
RESULTS 
Table 1 shows the relationship of symptom-
atic CMV disease to the immunosuppressives 
used. Thirty-two of 53 patients who received 
OKT3 developed CMV infection. Thirteen 
(40%) or these developed symptoms. including 
seven with a viral syndrome and six with 
disseminated CMV disease, Five of six 
patients with disseminated CMV disease had 
primary CMV infection. Of 23 patients with 
CMV infection who did not receive OKT3, 14 
(60%) were symptomatic, including nine with 
a viral syndrome and five with localized CMV 
disease. Thus the number of symptomatic 
patients among those who received OKT3 did 
not differ significantly from those who did not 
receive OKT3 (40% v 60%). However. dis-
seminated CMV infection occurred in six 
(\ 8%) of 32 patients who received OKT3 but 
in none of 23 patients who did not get OKT3 
(P = .06). 
Of 95 recipients seropositive for HSV anti-
bodies. 39 (41 %) developed typical mucocuta-
neous HSV lesions including 29 patients with 
oral HSV and ten with genital HSV. Two 
patients developed HSV esophagitis, and two 
had HSV hepatitis. The group treated with 
OKT3 had more symptomatic illness due to 
HSV (22 of 54, 54%) as compared with 
patients who did not get OKT3 (13 of 41, 
32%) (P = .05). 
DISCUSSION AND CONCLUSION 
Several studies have documented increased 
morbidity associated with CMV infection in 
renal transplant patients receiving ATG. Our 
data show that the frequency of overall symp-
tomatic CMV disease was not influenced by 
OKT3. OKT3, however, appeared to increase 
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Table 1. Relationship of Symptomatic CMV Disease to Additional Immunosuppression 
Additional Total Evaluable No. With Viral No. With Localized 
Immunosuppression Patients No. Infected No. Symptomatic Syndrome CMV Disease 
OKT3- 53 32- 13 (40%) 7 0 6t 
No OKT3 40 23t 14 (60%) 9 5 0 
Total patients 93 55 27 16 5 6 
- All patients treated with OKT3 got additional steroids; 1 7 of 32 infected patients also received Aza. 
tProportion of patients with disseminated CMV disease treated with OKT3 compared with patients who did not 
OKT3 (P - .06). 
tTwenty patients received additional steroids only. two received additional Aza only. and one patient did not race;... 
additional immunosuppression. 
the risk of disseminated CMV disease, partic-
ularly in patients with primary CMV infec-
tion. These findings may help to identify 
patients at highest risk for severe or fatal 
CMV infection. 
As reported in other organ allograft recip-
ient groups, most HSV infections are due to 
reactivation of latent virus.2 A few studies 
have correlated the use of antilymphocyte 
preparations with an increased risk of reacti-
vation and symptomatic illness due to HSV. 
Similar data are not available for OKT3, but 
we observed a higher frequency 
symptomatic HSV infections in OKT3. 
treated, seropositive patients. Most of these 
were mucocutaneous infections and therefore 
not life threatening. 
In conclusion, OKT3 treatment is asso-
ciated with a higher risk of disseminated 
CMV infection, particularly in patients with 
primary CMV infection. It also increased the 
frequency of symptomatic HSV infection in 
HSV -seropositive liver transplant recipients. 
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